Middle East psoriasis drugs market Size, Share, Growth Drivers, Trends, Opportunities & Forecast 2025–2030
Description
Middle East Psoriasis Drugs Market Overview
The Middle East Psoriasis Drugs Market is valued at USD 1.3 billion, based on a five-year historical analysis. This growth is primarily driven by the increasing prevalence of psoriasis, rising awareness about chronic inflammatory skin diseases, and advancements in biologic and targeted drug formulations. The market is also supported by expanding healthcare infrastructure, increased access to specialty care, and the introduction of innovative therapies that address diverse patient needs .
Countries such as Saudi Arabia, the United Arab Emirates, and Turkey dominate the market due to their robust healthcare systems, high disposable incomes, and increasing investments in healthcare. These nations have a significant number of dermatology clinics and hospitals, facilitating the availability and accessibility of psoriasis treatments and supporting market growth .
In 2023, the Saudi Arabian government implemented the "National Health Transformation Program" under Vision 2030, issued by the Ministry of Health, which includes initiatives to improve access to dermatological treatments such as psoriasis drugs. This program provides funding for research and development, expands insurance coverage, and offers subsidies for patients, ensuring broader access to effective therapies .
Middle East Psoriasis Drugs Market Segmentation
By Drug Class:
The market is segmented into various drug classes, including Tumor Necrosis Factor (TNF) Inhibitors, Interleukin Inhibitors (IL-17, IL-12/23, IL-23), Vitamin D Analogues, Corticosteroids, Retinoids, Calcineurin Inhibitors, and Others. Among these, TNF Inhibitors and Interleukin Inhibitors are leading the market due to their effectiveness in treating moderate to severe psoriasis. The increasing adoption of biologics and targeted therapies, particularly in the form of self-injectable and long-acting agents, is contributing to the growth of these segments .
By Route of Administration:
The market is categorized based on the route of administration, which includes Oral, Topical, and Injectable forms. Injectable treatments, particularly biologics, are gaining traction due to their rapid efficacy and convenience for patients with severe psoriasis. Topical treatments remain popular for mild to moderate cases, while oral medications are also widely used, contributing to the overall market dynamics .
Middle East Psoriasis Drugs Market Competitive Landscape
The Middle East Psoriasis Drugs Market is characterized by a dynamic mix of regional and international players. Leading participants such as AbbVie Inc., Amgen Inc., Novartis AG, Johnson & Johnson (Janssen Biotech Inc.), Pfizer Inc., Eli Lilly and Company, Merck & Co., Inc., Sanofi S.A., Galderma S.A., UCB S.A., Stiefel Laboratories, Inc. (a GSK company), Takeda Pharmaceutical Company Limited, Sandoz International GmbH (Novartis division), Celgene Corporation (a Bristol Myers Squibb company), Janssen Biotech, Inc. (Johnson & Johnson subsidiary) contribute to innovation, geographic expansion, and service delivery in this space.
AbbVie Inc.
2013
North Chicago, Illinois, USA
Amgen Inc.
1980
Thousand Oaks, California, USA
Novartis AG
1996
Basel, Switzerland
Johnson & Johnson (Janssen Biotech Inc.)
1886
New Brunswick, New Jersey, USA
Pfizer Inc.
1849
New York City, New York, USA
Company
Establishment Year
Headquarters
Market Share in Middle East Psoriasis Segment (%)
CAGR of Regional Psoriasis Drug Sales (%)
Number of Approved Psoriasis Products (Middle East)
Pipeline Strength (Number of Drugs in Development)
Regional Distribution Network Coverage (Countries/Outlets)
R&D Investment in Psoriasis (USD or % of Revenue)
Middle East Psoriasis Drugs Market Industry Analysis
Growth Drivers
Increasing Prevalence of Psoriasis:
The Middle East has witnessed a significant rise in psoriasis cases, with estimates indicating that approximately 3.5 million individuals are affected in the region. This increase is attributed to factors such as urbanization and lifestyle changes. The World Health Organization reported that the prevalence of psoriasis in the Middle East ranges from 0.1% to 3.0%, highlighting a growing patient population that drives demand for effective treatment options.
Advancements in Drug Formulations:
The pharmaceutical industry in the Middle East is experiencing rapid advancements in drug formulations, particularly in biologics and targeted therapies. In future, it is projected that over 20 new psoriasis treatments will be introduced, enhancing therapeutic options. These innovations are supported by increased R&D investments, which reached $1.5 billion, fostering a competitive landscape that encourages the development of more effective and safer psoriasis medications.
Rising Awareness and Diagnosis Rates:
Increased awareness of psoriasis and its treatment options has led to higher diagnosis rates across the Middle East. Health campaigns and educational initiatives have contributed to a 40% rise in diagnosed cases over the past five years. The region's healthcare systems are also improving diagnostic capabilities, with over 70% of dermatologists now utilizing advanced diagnostic tools, which further supports the growth of the psoriasis drugs market.
Market Challenges
High Cost of Innovative Treatments:
The introduction of innovative psoriasis treatments often comes with high costs, limiting accessibility for many patients. For instance, biologic therapies can exceed $35,000 annually per patient. This financial burden poses a significant challenge, particularly in lower-income areas of the Middle East, where healthcare budgets are constrained, leading to disparities in treatment access and adherence.
Limited Access to Healthcare Facilities:
Access to specialized healthcare facilities remains a challenge in many Middle Eastern countries. According to the World Bank, approximately 50% of the population in rural areas lacks access to dermatological services. This limitation affects timely diagnosis and treatment of psoriasis, resulting in increased disease burden and complications, which ultimately hinders market growth in the region.
Middle East Psoriasis Drugs Market Future Outlook
The future of the Middle East psoriasis drugs market appears promising, driven by ongoing advancements in treatment options and increasing healthcare investments. The region is likely to see a surge in personalized medicine approaches, enhancing treatment efficacy. Additionally, the integration of telemedicine is expected to improve patient access to dermatological care, facilitating timely interventions. As healthcare systems evolve, the focus on patient-centric care will further shape the market landscape, fostering innovation and improving patient outcomes.
Market Opportunities
Expansion of Telemedicine Services:
The rise of telemedicine presents a significant opportunity for the psoriasis drugs market. With an estimated 40% increase in telehealth consultations, patients can access dermatological care more conveniently. This trend is expected to continue, allowing for better management of psoriasis and increased adherence to treatment regimens, ultimately driving market growth.
Development of Biosimilars:
The growing interest in biosimilars offers a lucrative opportunity for market players. With the global biosimilars market projected to reach $150 billion in future, the Middle East can capitalize on this trend. Local manufacturers are increasingly investing in biosimilar development, which can provide cost-effective alternatives to expensive biologics, enhancing treatment accessibility for patients.
Please Note: It will take 5-7 business days to complete the report upon order confirmation.
The Middle East Psoriasis Drugs Market is valued at USD 1.3 billion, based on a five-year historical analysis. This growth is primarily driven by the increasing prevalence of psoriasis, rising awareness about chronic inflammatory skin diseases, and advancements in biologic and targeted drug formulations. The market is also supported by expanding healthcare infrastructure, increased access to specialty care, and the introduction of innovative therapies that address diverse patient needs .
Countries such as Saudi Arabia, the United Arab Emirates, and Turkey dominate the market due to their robust healthcare systems, high disposable incomes, and increasing investments in healthcare. These nations have a significant number of dermatology clinics and hospitals, facilitating the availability and accessibility of psoriasis treatments and supporting market growth .
In 2023, the Saudi Arabian government implemented the "National Health Transformation Program" under Vision 2030, issued by the Ministry of Health, which includes initiatives to improve access to dermatological treatments such as psoriasis drugs. This program provides funding for research and development, expands insurance coverage, and offers subsidies for patients, ensuring broader access to effective therapies .
Middle East Psoriasis Drugs Market Segmentation
By Drug Class:
The market is segmented into various drug classes, including Tumor Necrosis Factor (TNF) Inhibitors, Interleukin Inhibitors (IL-17, IL-12/23, IL-23), Vitamin D Analogues, Corticosteroids, Retinoids, Calcineurin Inhibitors, and Others. Among these, TNF Inhibitors and Interleukin Inhibitors are leading the market due to their effectiveness in treating moderate to severe psoriasis. The increasing adoption of biologics and targeted therapies, particularly in the form of self-injectable and long-acting agents, is contributing to the growth of these segments .
By Route of Administration:
The market is categorized based on the route of administration, which includes Oral, Topical, and Injectable forms. Injectable treatments, particularly biologics, are gaining traction due to their rapid efficacy and convenience for patients with severe psoriasis. Topical treatments remain popular for mild to moderate cases, while oral medications are also widely used, contributing to the overall market dynamics .
Middle East Psoriasis Drugs Market Competitive Landscape
The Middle East Psoriasis Drugs Market is characterized by a dynamic mix of regional and international players. Leading participants such as AbbVie Inc., Amgen Inc., Novartis AG, Johnson & Johnson (Janssen Biotech Inc.), Pfizer Inc., Eli Lilly and Company, Merck & Co., Inc., Sanofi S.A., Galderma S.A., UCB S.A., Stiefel Laboratories, Inc. (a GSK company), Takeda Pharmaceutical Company Limited, Sandoz International GmbH (Novartis division), Celgene Corporation (a Bristol Myers Squibb company), Janssen Biotech, Inc. (Johnson & Johnson subsidiary) contribute to innovation, geographic expansion, and service delivery in this space.
AbbVie Inc.
2013
North Chicago, Illinois, USA
Amgen Inc.
1980
Thousand Oaks, California, USA
Novartis AG
1996
Basel, Switzerland
Johnson & Johnson (Janssen Biotech Inc.)
1886
New Brunswick, New Jersey, USA
Pfizer Inc.
1849
New York City, New York, USA
Company
Establishment Year
Headquarters
Market Share in Middle East Psoriasis Segment (%)
CAGR of Regional Psoriasis Drug Sales (%)
Number of Approved Psoriasis Products (Middle East)
Pipeline Strength (Number of Drugs in Development)
Regional Distribution Network Coverage (Countries/Outlets)
R&D Investment in Psoriasis (USD or % of Revenue)
Middle East Psoriasis Drugs Market Industry Analysis
Growth Drivers
Increasing Prevalence of Psoriasis:
The Middle East has witnessed a significant rise in psoriasis cases, with estimates indicating that approximately 3.5 million individuals are affected in the region. This increase is attributed to factors such as urbanization and lifestyle changes. The World Health Organization reported that the prevalence of psoriasis in the Middle East ranges from 0.1% to 3.0%, highlighting a growing patient population that drives demand for effective treatment options.
Advancements in Drug Formulations:
The pharmaceutical industry in the Middle East is experiencing rapid advancements in drug formulations, particularly in biologics and targeted therapies. In future, it is projected that over 20 new psoriasis treatments will be introduced, enhancing therapeutic options. These innovations are supported by increased R&D investments, which reached $1.5 billion, fostering a competitive landscape that encourages the development of more effective and safer psoriasis medications.
Rising Awareness and Diagnosis Rates:
Increased awareness of psoriasis and its treatment options has led to higher diagnosis rates across the Middle East. Health campaigns and educational initiatives have contributed to a 40% rise in diagnosed cases over the past five years. The region's healthcare systems are also improving diagnostic capabilities, with over 70% of dermatologists now utilizing advanced diagnostic tools, which further supports the growth of the psoriasis drugs market.
Market Challenges
High Cost of Innovative Treatments:
The introduction of innovative psoriasis treatments often comes with high costs, limiting accessibility for many patients. For instance, biologic therapies can exceed $35,000 annually per patient. This financial burden poses a significant challenge, particularly in lower-income areas of the Middle East, where healthcare budgets are constrained, leading to disparities in treatment access and adherence.
Limited Access to Healthcare Facilities:
Access to specialized healthcare facilities remains a challenge in many Middle Eastern countries. According to the World Bank, approximately 50% of the population in rural areas lacks access to dermatological services. This limitation affects timely diagnosis and treatment of psoriasis, resulting in increased disease burden and complications, which ultimately hinders market growth in the region.
Middle East Psoriasis Drugs Market Future Outlook
The future of the Middle East psoriasis drugs market appears promising, driven by ongoing advancements in treatment options and increasing healthcare investments. The region is likely to see a surge in personalized medicine approaches, enhancing treatment efficacy. Additionally, the integration of telemedicine is expected to improve patient access to dermatological care, facilitating timely interventions. As healthcare systems evolve, the focus on patient-centric care will further shape the market landscape, fostering innovation and improving patient outcomes.
Market Opportunities
Expansion of Telemedicine Services:
The rise of telemedicine presents a significant opportunity for the psoriasis drugs market. With an estimated 40% increase in telehealth consultations, patients can access dermatological care more conveniently. This trend is expected to continue, allowing for better management of psoriasis and increased adherence to treatment regimens, ultimately driving market growth.
Development of Biosimilars:
The growing interest in biosimilars offers a lucrative opportunity for market players. With the global biosimilars market projected to reach $150 billion in future, the Middle East can capitalize on this trend. Local manufacturers are increasingly investing in biosimilar development, which can provide cost-effective alternatives to expensive biologics, enhancing treatment accessibility for patients.
Please Note: It will take 5-7 business days to complete the report upon order confirmation.
Table of Contents
90 Pages
- 1. Middle East psoriasis drugs Size, Share, Growth Drivers, Trends, Opportunities & – Market Overview
- 1.1. Definition and Scope
- 1.2. Market Taxonomy
- 1.3. Market Growth Rate
- 1.4. Market Segmentation Overview
- 2. Middle East psoriasis drugs Size, Share, Growth Drivers, Trends, Opportunities & – Market Size (in USD Bn), 2019–2024
- 2.1. Historical Market Size
- 2.2. Year-on-Year Growth Analysis
- 2.3. Key Market Developments and Milestones
- 3. Middle East psoriasis drugs Size, Share, Growth Drivers, Trends, Opportunities & – Market Analysis
- 3.1. Growth Drivers
- 3.1.1. Increasing prevalence of psoriasis
- 3.1.2. Advancements in drug formulations
- 3.1.3. Rising awareness and diagnosis rates
- 3.1.4. Government initiatives for healthcare improvement
- 3.2. Restraints
- 3.2.1. High cost of innovative treatments
- 3.2.2. Limited access to healthcare facilities
- 3.2.3. Regulatory hurdles in drug approval
- 3.2.4. Competition from alternative therapies
- 3.3. Opportunities
- 3.3.1. Expansion of telemedicine services
- 3.3.2. Development of biosimilars
- 3.3.3. Increasing investment in R&D
- 3.3.4. Collaborations with local healthcare providers
- 3.4. Trends
- 3.4.1. Shift towards personalized medicine
- 3.4.2. Growth in biologics and targeted therapies
- 3.4.3. Rising demand for combination therapies
- 3.4.4. Increased focus on patient-centric care
- 3.5. Government Regulation
- 3.5.1. Stricter drug approval processes
- 3.5.2. Enhanced pharmacovigilance requirements
- 3.5.3. Price control measures for essential drugs
- 3.5.4. Incentives for local manufacturing
- 3.6. SWOT Analysis
- 3.7. Stakeholder Ecosystem
- 3.8. Competition Ecosystem
- 4. Middle East psoriasis drugs Size, Share, Growth Drivers, Trends, Opportunities & – Market Segmentation, 2024
- 4.1. By Drug Class (in Value %)
- 4.1.1. Tumor Necrosis Factor (TNF) Inhibitors
- 4.1.2. Interleukin Inhibitors (IL-17, IL-12/23, IL-23)
- 4.1.3. Vitamin D Analogues
- 4.1.4. Corticosteroids
- 4.1.5. Retinoids
- 4.1.6. Calcineurin Inhibitors
- 4.1.7. Others
- 4.2. By Route of Administration (in Value %)
- 4.2.1. Oral
- 4.2.2. Topical
- 4.2.3. Injectable
- 4.3. By Distribution Channel (in Value %)
- 4.3.1. Retail Pharmacies
- 4.3.2. Hospital Pharmacies
- 4.3.3. Online Pharmacies
- 4.4. By Country (in Value %)
- 4.4.1. Saudi Arabia
- 4.4.2. United Arab Emirates
- 4.4.3. Qatar
- 4.4.4. Turkey
- 4.4.5. Egypt
- 4.4.6. Rest of Middle East
- 4.5. By Patient Demographics (in Value %)
- 4.5.1. Adults
- 4.5.2. Pediatrics
- 4.5.3. Geriatrics
- 4.6. By Treatment Type (in Value %)
- 4.6.1. Systemic Treatments
- 4.6.2. Topical Treatments
- 4.6.3. Phototherapy
- 5. Middle East psoriasis drugs Size, Share, Growth Drivers, Trends, Opportunities & – Market Cross Comparison
- 5.1. Detailed Profiles of Major Companies
- 5.1.1. AbbVie Inc.
- 5.1.2. Amgen Inc.
- 5.1.3. Novartis AG
- 5.1.4. Johnson & Johnson (Janssen Biotech Inc.)
- 5.1.5. Pfizer Inc.
- 5.2. Cross Comparison Parameters
- 5.2.1. Revenue from Psoriasis Drugs (USD, Middle East)
- 5.2.2. Market Share in Middle East Psoriasis Segment (%)
- 5.2.3. Number of Approved Psoriasis Products (Middle East)
- 5.2.4. Pipeline Strength (Number of Drugs in Development)
- 5.2.5. R&D Investment in Psoriasis (USD or % of Revenue)
- 6. Middle East psoriasis drugs Size, Share, Growth Drivers, Trends, Opportunities & – Market Regulatory Framework
- 6.1. Compliance Requirements and Audits
- 6.2. Certification Processes
- 7. Middle East psoriasis drugs Size, Share, Growth Drivers, Trends, Opportunities & – Market Future Size (in USD Bn), 2025–2030
- 7.1. Future Market Size Projections
- 7.2. Key Factors Driving Future Market Growth
- 8. Middle East psoriasis drugs Size, Share, Growth Drivers, Trends, Opportunities & – Market Future Segmentation, 2030
- 8.1. By Drug Class (in Value %)
- 8.2. By Route of Administration (in Value %)
- 8.3. By Distribution Channel (in Value %)
- 8.4. By Patient Demographics (in Value %)
- 8.5. By Treatment Type (in Value %)
- 8.6. By Region (in Value %)
- Disclaimer
- Contact Us
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
